World journal of clinical oncology最新文献

{"title":"Silica nanoparticle design for colorectal cancer treatment: Recent progress and clinical potential.","authors":"Jin Meng, Zhi-Gang Wang, Xiu Zhao, Ying Wang, De-Yu Chen, De-Long Liu, Cheng-Chun Ji, Tian-Fu Wang, Li-Mei Zhang, Hai-Xia Bai, Bo-Yang Li, Yuan Liu, Lei Wang, Wei-Gang Yu, Zhi-Tao Yin","doi":"10.5306/wjco.v15.i6.667","DOIUrl":"10.5306/wjco.v15.i6.667","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common cause of cancer death. Nanotherapies are able to selectively target the delivery of cancer therapeutics, thus improving overall antitumor efficiency and reducing conventional chemotherapy side effects. Mesoporous silica nanoparticles (MSNs) have attracted the attention of many researchers due to their remarkable advantages and biosafety. We offer insights into the recent advances of MSNs in CRC treatment and their potential clinical application value.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"667-673"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms.","authors":"Mihnea-Alexandru Găman, Bahadar Singh Srichawla, Yong-Feng Chen, Poulami Roy, Arkadeep Dhali, Ahmed Nahian, Muhammad Romail Manan, Vincent Kipkorir, Richard Christian Suteja, Lakshmi Venkata Simhachalam Kutikuppala, Amelia Maria Găman, Camelia Cristina Diaconu","doi":"10.5306/wjco.v15.i6.717","DOIUrl":"10.5306/wjco.v15.i6.717","url":null,"abstract":"<p><p>Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are often the cause of death in this population of patients. Herein, we provide a brief overview of dyslipidemia and metabolic syndrome and their epidemiology in MPNs and examine the common molecular mechanisms between dyslipidemia, metabolic syndrome, and MPNs, with a special focus on cardiovascular risk, atherosclerosis, and thrombotic events. Furthermore, we investigate the impact of dyslipidemia and metabolic syndrome on the occurrence and survival of thrombosis in MPN patients, as well as the management of dyslipidemia in MPNs, and the impact of MPN treatment on serum lipid concentrations, particularly as side/adverse effects reported in the context of clinical trials.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"717-729"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic oncological therapy in breast cancer patients on dialysis.","authors":"Salman Khan, Ghada Araji, Ekrem Yetiskul, Praneeth Reddy Keesari, Fadi Haddadin, Zaid Khamis, Varun Chowdhry, Muhammad Niazi, Sarah Afif, Meekoo Dhar, Suzanne El-Sayegh","doi":"10.5306/wjco.v15.i6.730","DOIUrl":"10.5306/wjco.v15.i6.730","url":null,"abstract":"<p><p>The advancement of renal replacement therapy has significantly enhanced the survival rates of patients with end-stage renal disease (ESRD) over time. However, this prolonged survival has also been associated with a higher likelihood of cancer diagnoses among these patients including breast cancer. Breast cancer treatment typically involves surgery, radiation, and systemic therapies, with approaches tailored to cancer type, stage, and patient preferences. However, renal replacement therapy complicates systemic therapy due to altered drug clearance and the necessity for dialysis sessions. This review emphasizes the need for optimized dosing and administration strategies for systemic breast cancer treatments in dialysis patients, aiming to ensure both efficacy and safety. Additionally, challenges in breast cancer screening and diagnosis in this population, including soft-tissue calcifications, are highlighted.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"730-744"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sleep on gastrointestinal cancer.","authors":"Joshua Lo, Pahnwat T Taweesedt, Makoto Kawai","doi":"10.5306/wjco.v15.i6.677","DOIUrl":"10.5306/wjco.v15.i6.677","url":null,"abstract":"<p><p>Sleep problems have become a significant public health concern, affecting a large portion of the global population and have been linked to increased morbidity and mortality. The incidence of gastrointestinal (GI) cancers continues to rise, posing a substantial burden on healthcare systems worldwide. This editorial aims to delve into the impact of sleep on GI cancers, including esophageal, gastric, colorectal, hepatobiliary, and pancreatic cancer. Recent literature investigating the potential connections between GI cancers and sleep was reviewed. We considered aspects such as sleep duration, sleep disorders, and circadian rhythmicity, in order to explore the underlying mechanisms that can contribute to the development of GI cancers and propose avenues for future research.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"677-683"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting liver function after hemihepatectomy in patients with hepatocellular carcinoma using different modalities.","authors":"Erfan Taherifard, Anwaar Saeed","doi":"10.5306/wjco.v15.i6.783","DOIUrl":"10.5306/wjco.v15.i6.783","url":null,"abstract":"<p><p>In response to Dr. Yue <i>et al</i>'s study on prognostic factors for post-hemihepatectomy outcomes in hepatocellular carcinoma (HCC) patients, this critical review identifies methodological limitations and proposes enhancements for future research. While the study identifies liver stiffness measure and standard residual liver volume as potential predictors, concerns regarding small sample size, reliance on biochemical markers for safety assessment, and inadequate adjustment for confounding variables are raised. Recommendations for rigorous methodology, including robust statistical analysis, consideration of confounding factors, and selection of outcome measures with clinical components, are proposed to strengthen prognostic assessments. Furthermore, validation of novel evaluation models is crucial for enhancing clinical applicability and advancing understanding of postoperative outcomes in patients with HCC undergoing hemihepatectomy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"783-785"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of the contemporary diagnosis and management approaches for anaplastic thyroid carcinoma.","authors":"Shu-Yue Zhou, Lian-Xiang Luo","doi":"10.5306/wjco.v15.i6.674","DOIUrl":"10.5306/wjco.v15.i6.674","url":null,"abstract":"<p><p>Thyroid carcinoma is a complex disease with several types, the most common being well-differentiated and undifferentiated. The latter, \"undifferentiated carcinoma\", also known as anaplastic thyroid carcinoma (ATC), is a highly aggressive malignant tumor accounting for less than 0.2% of all thyroid carcinomas and carries a poor prognosis with a median survival of 5 months. <i>BRAF</i> gene mutations are the most common molecular factor associated with this type of thyroid carcinoma. Recent advances in targeted biological agents, immunotherapy, stem cell therapy, nanotechnology, the dabrafenib/trametinib combination therapy, immune checkpoint inhibitors (ICI) and artificial intelligence offer novel treatment options. The combination therapy of dabrafenib and trametinib is the current standard treatment for patients with <i>BRAF-V600E</i> gene mutations. Besides, the dabrafenib/trametinib combination therapy, ICI, used alone or in combination with targeted therapies have raised some hopes for improving the prognosis of this deadly disease. Younger age, earlier tumor stage and radiotherapy are all prognostic factors for improved outcomes. Ultimately, therapeutic regimens should be tailored to the individual patient based on surveillance and epidemiological data, and a multidisciplinary approach is essential.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"674-676"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tankyrase 2 promotes lung cancer cell malignancy.","authors":"Ying Wang, Yong-Jun Zhang","doi":"10.5306/wjco.v15.i6.755","DOIUrl":"10.5306/wjco.v15.i6.755","url":null,"abstract":"<p><strong>Background: </strong>Tankyrase 2 (TNKS2) is a potential candidate molecular target for the prognosis and treatment of non-small cell lung cancer (NSCLC), but its biological functions are unclear.</p><p><strong>Aim: </strong>To investigate the biological functions of TNKS2 in NSCLC.</p><p><strong>Methods: </strong>Using a lentiviral vector, we generated H647 model cells with TNKS2 knockdown by RNA interference and A549 model cells with TNKS2 overexpression by transfection with a TNKS2 overexpressing plasmid. Increased and decreased expression levels of TNKS2 in the two cell lines were verified using real-time reverse transcriptase-polymerase chain reaction and Western blot analyses. Cell apoptosis, proliferation, and migration were determined using flow cytometry, carboxyfluorescein succinimidyl ester staining, and scratch assay, respectively. Immunofluorescence staining was conducted to examine TNKS2 and β-catenin expression levels in the two transfected cell lines and the non-transfected cells.</p><p><strong>Results: </strong>TNKS2 mRNA and protein expression was significantly higher in the highly malignant NCI-H647 cells, while it remained at a low level in the less malignant A549 cells. Lentivirus-mediated overexpression of TNKS2 in A549 cells resulted in a 3-fold increase in gene expression and a 1.7-fold increase in protein expression (<i>P</i> < 0.01). Conversely, shRNA interference targeting <i>TNKS2</i> Led to an 8-fold decrease in gene expression and a 3-fold decrease in protein expression (<i>P</i> < 0.01) in NCI-H647 cells. Furthermore, the cell apoptosis rate was significantly reduced (50%) and cell migration rate was increased (35%) in the TNKS2 overexpression group than in the control group (<i>P</i> < 0.05). In contrast, sh<i>TNKS2</i> promoted apoptosis by more than one fold and reduced migration by 60% (<i>P</i> < 0.05). Immunofluorescence analysis revealed enhanced nuclear localization of β-catenin fluorescence signal associated with high TNKS2 expression levels. Western blot analysis investigating TNKS2/β-catenin-related proteins indicated consistent changes between TNKS2 and β-catenin expression in lung cancer cells, whereas Axin displayed an opposite trend (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The obtained results revealed that TNKS2 may serve as an adverse prognostic factor and a potential therapeutic target in NSCLC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"755-764"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and distinct prognostic determinants of individuals with hepatosplenic T-cell lymphoma over the past two decades.","authors":"Ayrton Bangolo, Pierre Fwelo, Shraboni Dey, Tanni Sethi, Sowmya Sagireddy, Jawaria Chatta, Ashish Goel, Sneha Nagpaul, Eric Pin-Shiuan Chen, Chiranjeeve Saravanan, Sheeja Gangan, Joel Thomas, Sarah Potiguara, Vignesh K Nagesh, Daniel Elias, Charlene Mansour, Prajakta H Ratnaparkhi, Priyanshu Jain, Midhun Mathew, Taylor Porter, Shadiya Sultan, Shailaja Abbisetty, Linh Tran, Megha Chawla, Abraham Lo, Simcha Weissman, Christina Cho","doi":"10.5306/wjco.v15.i6.745","DOIUrl":"10.5306/wjco.v15.i6.745","url":null,"abstract":"<p><strong>Background: </strong>Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive peripheral T-cell lymphoma with historically dismal outcomes, representing less than one percent of non-Hodgkin lymphomas. Given its rarity, the true incidence of HSTCL is unknown and most data have been extrapolated through case reports. To the best of our knowledge, the largest and most up to date study addressing the epidemiology and outcomes of patients with HSTCL in the United States covered a period from 1996 to 2014, with a sample size of 122 patients.</p><p><strong>Aim: </strong>To paint the most updated epidemiological picture of HSTCL.</p><p><strong>Methods: </strong>A total of 186 patients diagnosed with HSTCL, between 2000 and 2017, were ultimately enrolled in our study by retrieving data from the Surveillance, Epidemiology, and End Results database. We analyzed demographics, clinical characteristics, and overall mortality (OM) as well as cancer-specific mortality (CSM) of HSTCL. Variables with a <i>P</i> value < 0.01 in the univariate Cox regression were incorporated into the multivariate Cox model to determine the independent prognostic factors, with a hazard ratio of greater than 1 representing adverse prognostic factors.</p><p><strong>Results: </strong>Male gender was the most represented. HSTCL was most common in middle-aged patients (40-59) and less common in the elderly (80+). Non-Hispanic whites (60.75%) and non-Hispanic blacks (20.97%) were the most represented racial groups. Univariate Cox proportional hazard regression analysis of factors influencing all-cause mortality showed a higher OM among non-Hispanic black patients. CSM was also higher among non-Hispanic blacks and patients with distant metastasis. Multivariate Cox proportional hazard regression analysis of factors affecting CSM revealed higher mortality in patients aged 80 or older and non-Hispanic blacks.</p><p><strong>Conclusion: </strong>Overall, the outlook for this rare malignancy is very grim. In this retrospective cohort study of the United States population, non-Hispanic blacks and the elderly had a higher CSM. This data highlights the need for larger prospective studies to investigate factors associated with worse prognosis in one ethnic group, such as treatment delays, which have been shown to increase mortality in this racial/ethnic group for other cancers.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"745-754"},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal cancer: Getting the perspective and context right.","authors":"Jun De Lu, Kok Yang Tan","doi":"10.5306/wjco.v15.i5.599","DOIUrl":"10.5306/wjco.v15.i5.599","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a significant global health burden, being the third leading cancer globally. Its incidence has been observed to be higher in developed regions such as North America and Europe with geographical variations in mortality rates. Efforts to address this disease burden include promoting early detection through screening and implementing treatment strategies to improve patient outcomes. With the growing and aging population, the incidence of CRC will undoubtedly increase. These epidemiological trends will mean that healthcare professionals will increasingly encounter CRC in more complex patients. Hence, it becomes imperative to have a deeper appreciation of the pathophysiology of CRC and understand the intricate interplay between a patient's physiology and their goals of care before offering treatment. This review article will aim to encapsulate the important nuances and perspectives of managing this disease in the context of an elderly patient.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 5","pages":"599-602"},"PeriodicalIF":2.8,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the economic crisis and drug shortage on Lebanese cancer patients' care.","authors":"Dollen Eid, Jad Jabbour, Elissar Moujaes, Hampig Raphael Kourie, Maissa Safieddine, Joseph Kattan","doi":"10.5306/wjco.v15.i5.644","DOIUrl":"10.5306/wjco.v15.i5.644","url":null,"abstract":"<p><strong>Background: </strong>As a consequence of the economic crisis, the sociopolitical instability and the advent of the coronavirus disease-19 pandemic, nested challenges faced the Lebanese healthcare system. These have resulted in critical shortages of essential resources, including medications vital for oncologic patients.</p><p><strong>Aim: </strong>To assess the ramifications of the ongoing economic crisis on oncology patient care focusing on our outpatient oncology department.</p><p><strong>Methods: </strong>A questionnaire was distributed during the month of February 2022 to oncology patients in Hôtel Dieu de France University Hospital in Beirut during their outpatient therapy. The primary objective was to assess the far-reaching impact of the economic crisis on patient care and the resulting psychological implications.</p><p><strong>Results: </strong>Among 182 interviewed patients, 31.87% experienced treatment interruption mainly due to acute drug shortages. Despite 87.91% of the patients benefiting from third-party coverage, 69.60% had to self-pay for their medications leading to 69.78% of patients perceiving that healthcare was more difficult to access after 2020. Psychologically, one-third of the patients exhibited symptoms of anxiety and/or depression, with 7 patients reporting suicidal ideations. Notably, 37.93% of patients who interrupted cancer treatment reported a history of comorbidities, and 89.66% who altered their treatment cited financial difficulties.</p><p><strong>Conclusion: </strong>Lebanese cancer patients face complex challenges spanning economic, healthcare, and psychological realms. Income inequalities exacerbated by the economic crisis hindered healthcare access.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 5","pages":"644-652"},"PeriodicalIF":2.8,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}